All In Biotech

Drug Trial Radar · NCT05221840

A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

A Phase III, Double-blind, Placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,051 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,051

Actual

Start

Feb 7, 2022

Primary completion

Jan 8, 2027

Study completion Jul 2, 2030

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Feb 3, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase III, randomised, double-blind, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) in combination with oleclumab (MEDI9447) or durvalumab (MEDI4736) with monalizumab (IPH2201) in adults with locally advanced (Stage III), unresectable NSCLC, who have not progressed following platinum-based cCRT.

Conditions

  • Non-Small Cell Lung Cancer

Interventions

  • DurvalumabDrug

    Durvalumab IV (intravenous infusion)

  • OleclumabDrug

    Oleclumab IV (intravenous infusion)

  • MonalizumabDrug

    Monalizumab IV (intravenous infusion)

  • PlaceboOther

    Placebo IV (intravenous infusion)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Surival (PFS)Time frame: Up to 5 years after first patient randomized.

Locations

202 sites in 20 countries. Site status is shown where the registry gives one.

  • Research Site

    San Diego, California

  • Research Site

    New Haven, Connecticut

  • Research Site

    Stuart, Florida

  • Research Site

    Urbana, Illinois

  • Research Site

    New Albany, Indiana

  • Research Site

    Lexington, Kentucky

  • Research Site

    Louisville, Kentucky

  • Research Site

    Annapolis, Maryland

  • Research Site

    Baltimore, Maryland

  • Research Site

    Baltimore, Maryland

  • Research Site

    Bethesda, Maryland

  • Research Site

    Grand Rapids, Michigan

  • Research Site

    Duluth, Minnesota

  • Research Site

    Billings, Montana

  • Research Site

    Ridgewood, New Jersey

  • Research Site

    Ithaca, New York

  • Research Site

    Greensboro, North Carolina

  • Research Site

    Cleveland, Ohio

  • Research Site

    Cleveland, Ohio

  • Research Site

    Maumee, Ohio

  • Research Site

    Portland, Oregon

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    York, Pennsylvania

  • Research Site

    Sioux Falls, South Dakota

  • Research Site

    Houston, Texas

  • Research Site

    Charlottesville, Virginia

  • Research Site

    Fairfax, Virginia

  • Research Site

    Fredericksburg, Virginia

  • Research Site

    Richmond, Virginia

  • Research Site

    Richland, Washington

  • Research Site

    Spokane, Washington

  • Research Site

    Tacoma, Washington

  • Research Site

    Milwaukee, Wisconsin

  • Research Site

    Box Hill, Australia

  • Research Site

    East Melbourne, Australia

  • Research Site

    Elizabeth Vale, Australia

  • Research Site

    Gosford, Australia

  • Research Site

    Heidelberg, Australia

  • Research Site

    Kogarah, Australia

  • Research Site

    South Brisbane, Australia

Showing 40 of 202 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.